United Therapeutics (UTHR) files Form 144 for 700-share sale via Morgan Stanley

Rhea-AI Filing Summary

United Therapeutics Corp (UTHR) filed a Form 144 disclosing a proposed sale of 700 shares of common stock through Morgan Stanley Smith Barney LLC, scheduled approximately on 09/09/2025. The filing lists an aggregate market value of $280,203.00 for the shares and shows 45,226,262 shares outstanding. The securities were acquired as restricted stock from the issuer in two grants dated 06/26/2025 (110 shares) and 07/25/2025 (590 shares). The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information and that intentional misstatements are a federal offense.

Positive

• Rule 144 notice filed disclosing the proposed sale of 700 shares (aggregate market value $280,203.00)
• Broker identified as Morgan Stanley Smith Barney LLC and sale directed to occur on NASDAQ, meeting standard disclosure elements

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale notice; transaction size is immaterial relative to shares outstanding.

The Form 144 records a proposed sale of 700 shares with an aggregate market value of $280,203.00 versus 45.2 million shares outstanding, indicating the transaction is small in absolute and relative terms. The securities were recent restricted stock grants from the issuer, suggesting these are internal compensation-related shares becoming eligible for sale. There is no disclosure of prior sales in the past three months. This filing is informational and unlikely to be material to valuation or trading given the small size.

Compliance Officer

TL;DR: Filing meets Rule 144 notice requirements and includes required attestations.

The notice identifies the broker, class, number of shares, approximate sale date, acquisition dates, and nature of acquisition (restricted stock), and contains the required attestation about material nonpublic information and penalties for false statements. From a regulatory perspective, the form appears to include the essential elements for a Rule 144 sale notice and does not report any aggregated prior sales in the past three months.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	700	280203.00	45226262	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/26/2025	Restricted Stock	Issuer			110	06/26/2025	Not Applicable
Common	07/25/2025	Restricted Stock	Issuer			590	07/25/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does United Therapeutics' (UTHR) Form 144 disclose?

The Form 144 discloses a proposed sale of 700 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $280,203.00 and an approximate sale date of 09/09/2025.

How and when were the shares to be sold acquired?

The securities were acquired as restricted stock from the issuer: 110 shares on 06/26/2025 and 590 shares on 07/25/2025.

Does the filing report any securities sold in the past three months?

No. The Form 144 states "Nothing to Report" for securities sold during the past three months.

What assurances does the seller provide in the Form 144?

The seller represents they do not know any material adverse information about the issuer not publicly disclosed and the form includes the standard federal criminal penalties warning for intentional misstatements.

Through which exchange is the sale planned?

The proposed sale is planned on NASDAQ.